Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 841 AL 855

Effect of nicotine on the pharmacokinetics of levodopa

Kyaw WT, Nagai M, Kaneta M, Kubo M, Nishikawa N, Tsujii T, Iwaki H, Nomoto M.

Clin Neuropharmacol. 2013 Mar-Apr;36(2):46-51. doi: 10.1097/WNF.0b013e31827fd9cd.

Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease

Müller T, Jugel C, Muhlack S, Klostermann F.

Clin Neuropharmacol. 2013 Mar-Apr;36(2):52-4. doi: 10.1097/WNF.0b013e318283fa18.

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases

Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, Toda T, Wada K, Nagai Y.

Neurotherapeutics. 2013 Jul;10(3):440-6. doi: 10.1007/s13311-013-0184-7.

Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity

Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M.

ASN Neuro. 2013 Apr 30;5(2):113-39. doi: 10.1042/AN20120066.

Oxidized phosphatidylcholines in membrane-level cellular signaling: from biophysics to physiology and molecular pathology

Volinsky R, Kinnunen PK.

FEBS J. 2013 Jun;280(12):2806-16. doi: 10.1111/febs.12247. Epub 2013 Apr 17.

Psychiatric care in Parkinson's disease

Quelhas R.

J Psychiatr Pract. 2013 Mar;19(2):118-41. doi: 10.1097/01.pra.0000428558.94329.6d.

The effect of step-synchronized vibration on patients with Parkinson's disease: case studies on subjects with freezing of gait or an implanted deep brain stimulator

Winfree KN, Pretzer-Aboff I, Hilgart D, Aggarwal R, Behari M, Agrawal SK.

IEEE Trans Neural Syst Rehabil Eng. 2013 Sep;21(5):806-11. doi: 10.1109/TNSRE.2013.2250308. Epub 2013 Mar 14.

The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease

Giladi N, Boroojerdi B, Surmann E.

J Neural Transm (Vienna). 2013 Sep;120(9):1321-9. doi: 10.1007/s00702-013-1001-5. Epub 2013 Mar 19.

Mild cognitive impairment in Parkinson's disease

Korczyn AD.

J Neural Transm (Vienna). 2013 Apr;120(4):517-21. doi: 10.1007/s00702-013-1006-0. Epub 2013 Mar 19.

Pedunculopontine nucleus: functional organization and clinical implications

Benarroch EE.

Neurology. 2013 Mar 19;80(12):1148-55. doi: 10.1212/WNL.0b013e3182886a76.

Early Alzheimer's and Parkinson's disease pathology in urban children: Friend versus Foe responses--it is time to face the evidence

Calderón-Garcidueñas L, Franco-Lira M, Mora-Tiscareño A, Medina-Cortina H, Torres-Jardón R, Kavanaugh M.

Biomed Res Int. 2013;2013:161687. doi: 10.1155/2013/161687. Epub 2013 Feb 7.

Targeting erythropoietin for chronic neurodegenerative diseases

Chong ZZ, Shang YC, Mu Y, Cui S, Yao Q, Maiese K.

Expert Opin Ther Targets. 2013 Jun;17(6):707-20. doi: 10.1517/14728222.2013.780599. Epub 2013 Mar 20.

α-Synuclein and mitochondria: partners in crime?

Nakamura K.

Neurotherapeutics. 2013 Jul;10(3):391-9. doi: 10.1007/s13311-013-0182-9.

Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease

Lv Q, Zhang B.

Neurosci Bull. 2013 Oct;29(5):661-9. doi: 10.1007/s12264-013-1329-8. Epub 2013 Mar 20.

Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Daneault JF, Carignan B, Sadikot AF, Panisset M, Duval C.

BMC Med. 2013 Mar 20;11:76. doi: 10.1186/1741-7015-11-76.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias